Clinical trials in San Sebastián de la Gomera

In San Sebastián de la Gomera, researchers are conducting two active studies that address allergic rhinitis/rhinoconjunctivitis caused by indoor allergens, primarily house dust mite and Blomia tropicalis. Both trials are recruiting participants to evaluate new therapeutic approaches and improve diagnostic accuracy.

• Assess the effectiveness of an allergy injection for patients with dust‑mite‑related respiratory symptoms.
• Determine the optimal concentration of allergen extract for accurate prick test diagnostics.
• Measure treatment outcomes such as symptom reduction and quality‑of‑life improvement.
• Compare diagnostic performance across different allergen preparations.

The results aim to guide clinicians in selecting the most effective allergen‑specific therapies and reliable testing methods for environmental allergy sufferers.

A parallel investigation in the same city focuses on ocular manifestations of allergen exposure, targeting patients who experience eye irritation linked to house dust mite and Blomia tropicalis sensitivities.

• Evaluate how the allergy injection affects eye itching, redness, and tearing.
• Analyze the safety profile of the treatment for ocular tissues.
• Compare patient‑reported eye symptom scores before and after therapy.
• Refine the prick test protocol for detecting eye‑specific allergic reactions.

Findings are expected to improve management strategies for allergic eye disease and support personalized care for affected individuals.

The third thematic area explores the underlying immune mechanisms driving allergy to dust mites and Blomia tropicalis, providing insight into broader immune system disorders.

• Characterize the IgE‑mediated immune response to specific dust‑mite allergens.
• Validate the sensitivity and specificity of new allergen extract concentrations for diagnostic use.
• Assess biomarkers that predict therapeutic success with immunotherapy.
• Support development of personalized treatment plans based on immune profiling.

This research will help clinicians tailor interventions that modulate immune activity, enhancing outcomes for patients with allergic and related immune conditions.